Teleflex to Promote the Rise of the Vascular Access Specialist & Demonstrate Arrow® Brand Products at the Association for Va...
September 16 2016 - 6:45AM
Business Wire
Teleflex Incorporated (NYSE: TFX), a leading provider of medical
technologies for critical care and surgery, will focus on the rise
of the vascular access specialist with its vascular access
technologies and new educational platform at the 30th Annual
Scientific Meeting of the Association for Vascular Access (AVA), in
Orlando, Florida, to be held September 16-19, 2016.
The rise of the vascular access specialist has become a part of
the mission statement for Teleflex’s Arrow® Vascular Access
business. We believe in striving for zero complications to become
reality within vascular access, and we believe that expertise in
vascular access can help achieve this goal. Teleflex supports this
goal with education, advocating scope of practice expansion and
innovative technology. At AVA this year, we will be showcasing our
educational and vascular products to support the rise of the
vascular access specialist.
Teleflex will be unveiling the Teleflex Academy, a new online
clinical education platform. The booth educational experience for
the Teleflex Academy at this year’s AVA will focus on every aspect
of vascular access, inspiring confidence, enhancing skills and
enabling clinicians to make an even bigger difference in their
patient’s lives. Teleflex believes that quality education is the
first step in fostering the expansion of skills and helping to
shape clinical practice.
Teleflex is excited to launch the Arrow® Midline with
Chlorag+ard® Technology, adding to the family of antithrombogenic
and antimicrobial protected catheters.1,2
The company will offer its popular Vascular Access Procedural
Cadaver Lab onsite, training on many different vascular access
procedures. Teleflex will also have clinical education activities
at its booth, where models will be used to demonstrate the full
range of the company’s vascular access devices.
At the breakfast symposium, “Rising to the Challenge: How
Vascular Access Specialists Started Placing CVCs,” attendees will
be educated on the importance of the evolution of the vascular
access specialist. This course highlights the experiences of
clinicians who have made the journey to expand their roles to place
central venous catheters, and describes the clinical process and
materials needed to develop a vascular access team.
The platinum showcase symposium, “Locking the Lumen…Consider the
Solutions!” will review why given today’s medical reimbursement
risks, facilities must explore all opportunities to reduce
potential vascular access complications. Locking solutions could
provide an additional layer of protection when used in conjunction
with proven protected catheter technology. The presentation will
address catheter colonization, intraluminal colonization and how
locking solutions and protected catheters address these.
The dinner symposium, “Strategy or Risk: the Use of Midline
Catheters”, will focus on the recent popularity of Midline
catheters, the role of a Midline, and how technology could be the
key to ensuring Midline success.
“The ‘Right Line, Right Patient, Right Time™’ has been at the
center of our Vascular business model for many years and we
continue to be the market leader in this philosophy,” said Jay
White, president and general manager of the Vascular Access
Division. “We have developed first class vascular educational
programs for vascular access clinicians. We are proud to provide
clinicians with solutions such as Chlorag+ard® Technology which
protects the catheter surface beyond initial insertion in addition
to tools to treat their patients with the best possible care. We
look forward to launching these clinical education and vascular
products at this year’s AVA meeting.”
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people’s lives. We apply
purpose driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference. For more information,
please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch® and Weck® – trusted brands united by a common
sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Chlorag+ard, Deknatel,
Hudson RCI, LMA, Pilling, Right Line, Right Patient, Right Time,
Rusch and Weck are trademarks or registered trademarks of Teleflex
Incorporated or its affiliates, in the U.S. and/or other countries.
All other trademarks are trademarks of their respective owners.©
2016 Teleflex Incorporated. All rights reserved. MC-002544
Rx Only
Contraindication:Chlorag+ard® Technology is
contraindicated for patients with known hypersensitivity to
chlorhexidine.
References:
- Data on file. As compared to uncoated
catheters, intravascular ovine model inoculated with Staph aureus.
No correlation between in vitro / in vivo testing methods and
clinical outcomes have currently been ascertained.
- In vitro data on file 2010. No
correlation between in vitro / in vivo testing methods and clinical
outcomes have currently been ascertained.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160916005053/en/
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Sep 2023 to Sep 2024